BHC - Bausch Health Companies Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
23.22
+0.30 (+1.31%)
As of 12:54PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close22.92
Open23.15
Bid23.13 x 800
Ask23.15 x 800
Day's Range22.94 - 23.79
52 Week Range17.20 - 28.45
Volume2,051,615
Avg. Volume4,818,667
Market Cap8.121B
Beta (3Y Monthly)0.70
PE Ratio (TTM)N/A
EPS (TTM)-9.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est30.29
Trade prices are not sourced from all markets
  • Bausch is 'the most integrated eye-care company in the wo...
    CNBC Videos16 days ago

    Bausch is 'the most integrated eye-care company in the wo...

    Jim Cramer speaks to Bausch Health Companies Chairman and CEO Joseph Papa about his company's turnaround, competition and 2019 prospects.

  • Why Bausch (BHC) is Poised to Beat Earnings Estimates Again
    Zacks3 hours ago

    Why Bausch (BHC) is Poised to Beat Earnings Estimates Again

    Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • All Signals Are Positive for Buying Abbott Laboratories
    InvestorPlaceyesterday

    All Signals Are Positive for Buying Abbott Laboratories

    Abbott Laboratories (NYSE:ABT) stock rose steadily in the last year and is up around 20% in that time. Though shares hover near yearly highs, thanks to a quick bounce from $66 to $71.42 recently, biotech investors should still consider investing in this company. Last quarter's strong results, plus a recent dividend hike, signal a healthy 2019 year for this medical appliance and equipment firm. Abbott Laboratories will report Q4 results on Jan. 23 that will likely repeat Q3 2018 results, which were posted last October. The firm reported sales of $7.7 billion, up 7.8% on an organic basis. Since divesting its Abbott Medical Optics ("AMO") and integrating St. Jude Medical vascular business, it is more focused on heart and diabetic machines. Diagnostics, medical devices, nutrition, and established pharmaceuticals all grew in the healthy single digits. ### Full-Year 2018 Forecast for ABT Stock Abbott forecast earnings of $2.87 to $2.89 (adjusted), reflecting growth of 15%. It owes its growth to developments in its medical devices. For example, the U.S. approved the FreeStyle Libre 14-day system, so sales should start adding to results. FreeStyle Libre 2 system and High Sensitive Troponin, available in Europe, will bring healthy geographic diversification to its revenue. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Retail Stocks to Buy for the Rise of Menswear On Dec. 16, 2018, Abbott declared a 32-cent a share quarterly dividend. This increase from 28-cents a share, or up 14.3%, gives investors a forward yield of 1.8%. This is below that of Bristol-Myers Squibb (NYSE:BMY), at 3.27%, Merck & Co. (NYSE:MRK), at 2.9%, or Pfizer (NYSE:PFE), at 3.39%. Medtronic (NYSE:MDT) has a comparable dividend yield of 2.29%. Despite dividend yields below that of comparable medical firms, this is still a bullish signal. Management is demonstrating its confidence in future cash flow growth and rewarding shareholders with income. Plus, the firm pays a higher dividend yield than the bottom 25% of dividend payers in the U.S. (according to simplywall.st). ### Abbott Balance Sheet Analysis Abbott's net worth increased in 2017 to $31.5 billion, but debt also rose, too, to $23.8 billion. This is due to the St. Jude Medical acquisition. Markets do not seem to care about the higher debt because its long term, the debt/equity ratio is only 0.62X, according to MacroTrends. In the drug space, Bausch Health Companies (NYSE:BHC) has a debt/equity of nearly 8x while Mylan N.V. (NASDAQ:MYL) is at 1.2X. The point here is that Abbot can handle the debt due to its healthy debt coverage. Its Operating cash flow of 26% exceeds its over 20% of total debt. Interest payment on the debt is covered by 4.8 times its EBIT. Abbott Laboratories debt levels increased from merger and acquisition activities. (Source: https://simplywall.st) ### Outlook for ABT Stock Synergies from the integration of Abbott's St Jude unit will save on costs. Because management puts an emphasis on improving its underlying gross margin, look for the unit to keep performing better and adding more to profits. The Alere unit, which will bring in $2 billion in revenue for fiscal 2018, will add positively to profits. Last year, Abbott stabilized and integrated the business. With that activity complete, it may concentrate on growing the business. As it happened that the strong flu season will benefit results, sustaining growth will depend on new product introductions from the unit. Based on the six analysts covering ABT stock, the average price target is $79.33, representing upside of 11%. Investors may build a bearish to neutral 10-year DCF Revenue Exit model that assumes revenue slowing in the single digits. Even in that scenario, the model from finbox.io would still suggest a fair value of $73, not far from the recent stock price of ABT. Abbott put a priority on its dividends over debt repayment. Its businesses are growing steadily and the product list is getting bigger. Cash flow growth will let the company meet its dividend payment obligations while paring debt levels over the long-term. ABT stock is suitable for income investors who want to own a growing medical appliances firm at a reasonable price. As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Growth Stocks for the Return of the Bull * The 10 Best Index Funds to Buy and Hold * 10 Lithium Stocks to Buy Despite the Market's Irrationality Compare Brokers The post All Signals Are Positive for Buying Abbott Laboratories appeared first on InvestorPlace.

  • Markityesterday

    See what the IHS Markit Score report has to say about Bausch Health Companies Inc.

    # Bausch Health Companies Inc ### NYSE:BHC View full report here! ## Summary * Perception of the company's creditworthiness is positive and improving * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BHC with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BHC. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.20 billion over the last one-month into ETFs that hold BHC are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Positive The current level displays a positive indicator with a strengthening bias over the past 1-month. BHC credit default swap spreads are decreasing and near the lowest level of the last three years, which indicates improvement in the market's perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire5 days ago

    Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2018 Financial Results On February 20

    LAVAL, Quebec , Jan. 18, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its fourth-quarter and full-year 2018 financial results on Wednesday, ...

  • Are Insiders Buying Bausch Health Companies Inc. (NYSE:BHC) Stock?
    Simply Wall St.5 days ago

    Are Insiders Buying Bausch Health Companies Inc. (NYSE:BHC) Stock?

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...

  • InvestorPlace6 days ago

    The Street Is Bullish on Facebook Stock

    Facebook (NASDAQ:FB) stock has shown some signs of life of late. FB stock hit its lowest levels in almost two years in December. But the New Year has been good to FB stock, which has risen over 10% in 2019. I'm still skeptical about FB stock, as I wrote last month. Facebook stock unquestionably is cheap. But the company's spending is rising in 2019 , which is one reason that the market cap of FB stock suffered the biggest single-day decline in stock market history in August . Meanwhile, regulators are still on the prowl, and Facebook's user growth almost has to decelerate, given its worldwide reach. But I'm clearly on the opposite side of Wall Street, which continues to embrace FB stock. That optimism no doubt has contributed to this year's gains. And if analysts are right, FB stock has more room to rise. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy as the Dollar Weakens ### The Street Defends Facebook Stock At least four analysts have made bullish arguments about FB stock in just the last two weeks. JPMorgan Chase called it a "best idea", and assigned Facebook stock a price target of $195. Barclays called FB "the best opportunity in large-cap Internet (stocks)." Baird, too, assigned FB stock a $195 target. And as InvestorPlace's Harriet Lefton noted this week, RBC Capital called Facebook stock one of its 10 best for 2019. Even Citron Research, better known as a short-seller of stocks like Bausch Health (NYSE:BHC) and Shopify (NYSE:SHOP), has been bullish on Facebook stock. Those analysts aren't alone: the average price target on Facebook stock, according to finviz.com, sits at $187. That figure suggests that FB stock can rise another 25% this year. The analysts' main points are different, but they share some similar themes. Citron and RBC both highlight the value of Instagram and WhatsApp, two of the company's platforms that haven't been monetized to the same extent as its namesake website. JPMorgan Chase noted that Facebook usage is "stickier than many think;" in other words, most users haven't left the site despite the negative publicity of 2018. Barclays agrees, as the firm predicts that FB will report higher-than-expected daily average users (DAUs) when it announces its Q4 earnings, likely later this month. And pretty much every bull points to the current valuation of FB stock, which is cheap. FB still trades at around 20 times analysts' consensus 2019 EPS estimate, and the valuation of Facebook stock is closer to 17 times after excluding the company's cash hoard. The valuation of FB stock suggests that its growth is pretty much coming to an end. And so it's not too surprising that analysts who don't believe the company's growth is over are arguing that FB stock should get more credit and higher multiples. ### FB Stock Ahead of Earnings The rising sentiment towards Facebook stock, both from analysts and investors, sets up an important fourth-quarter earnings report for FB. In a lot of ways, the bull case on FB is based on the idea that the bad news already is baked into FB stock at its current levels. We already know that the company's earnings growth is going to slow as its spending on security rises. CEO Mark Zuckerberg has apologized for the company's slow response to security issues, and he and his company are working to improve on that front. And so there's an obvious case that bulls can make in the wake of the Q4 report. Specifically, they can argue that the company's user-growth figures remain solid, showing that the public still trusts FB or at least still uses its services. Meanwhile, they will likely be able to say that the company's 2019 outlook remains roughly in- line with investors' already-low expectations. Facebook's revenue will likely still be poised to grow 25%+ this year (analysts' consensus estimate is 26.5%), reminding investors that the company is still growing. And the same analysts who are backing FB stock now will reaffirm their price targets or even raise them. FB stock will respond by rising, and the 2019 rally will continue. Truthfully, I wouldn't be surprised to see that scenario play out. Investors who are bullish on FB probably should look to buy FB ahead of its earnings. But from a longer-term perspective, FB stock is still facing a lot of risk. Indeed, the key question is whether the bad news really is behind Facebook stock. If it is, the company's Q4 numbers can give it somewhat of a fresh start, and its late-2018 lows look like a bottom. But if there's more bad news ahead for FB, the early-year gains of FB stock were just a false start. And actually, I can't quite shake the feeling that there's something else coming down the pike. As of this writing, Vince Martin has no positions in any securities mentioned. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Growth Stocks With the Future Written All Over Them * 7 Reasons Why Buffett's Bet on Apple Stock Is a Good One * 10 Companies That Could Post Decelerating Profits Compare Brokers The post The Street Is Bullish on Facebook Stock appeared first on InvestorPlace.

  • Bausch Health (BHC) Gains But Lags Market: What You Should Know
    Zacks8 days ago

    Bausch Health (BHC) Gains But Lags Market: What You Should Know

    Bausch Health (BHC) closed at $22.34 in the latest trading session, marking a +0.4% move from the prior day.

  • Is Bausch Health (BHC) Stock Undervalued Right Now?
    Zacks8 days ago

    Is Bausch Health (BHC) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Bausch Health Companies Inc.

    # Bausch Health Companies Inc ### NYSE:BHC View full report here! ## Summary * Perception of the company's creditworthiness is positive and improving * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for BHC with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BHC. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding BHC is favorable, with net inflows of $8.80 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Positive The current level displays a positive indicator with a strengthening bias over the past 1-month. BHC credit default swap spreads are decreasing and near the lowest level of the last three years, which indicates improvement in the market's perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know
    Zacks15 days ago

    Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know

    Bausch Health (BHC) closed the most recent trading day at $22.68, moving +1.43% from the previous trading session.

  • TheStreet.com15 days ago

    Can Bausch Health Convince the Charts of its Comeback Story?

    In his final "Executive Decision" segment during Monday night's Mad Money program, Jim Cramer sat down with Joe Papa, chairman and CEO of Bausch Health Cos. BHC was formerly known as Valeant which topped out in 2015 and subsequently fell sharply. Papa explained that Bausch has increased their research and development spending and is once again focused on innovation and organic growth.

  • CNW Group15 days ago

    Bausch Health's Canadian business positioned for growth in 2019

    Bausch Health's Canadian business positioned for growth in 2019

  • Cramer Remix: This chipmaker could have another bad quarter—but it's worth buying now
    CNBC16 days ago

    Cramer Remix: This chipmaker could have another bad quarter—but it's worth buying now

    Jim Cramer explains why it might be worth picking up shares of Micron now despite a possible negative quarter on the horizon.

  • Bausch Health Guidance Brings Option Bulls
    Schaeffer's Investment Research16 days ago

    Bausch Health Guidance Brings Option Bulls

    The company made the announcement at the J.P. Morgan Healthcare Conference

  • Implied Volatility Surging for Bausch (BHC) Stock Options
    Zacks16 days ago

    Implied Volatility Surging for Bausch (BHC) Stock Options

    Investors need to pay close attention to Bausch (BHC) stock based on the movements in the options market lately.

  • PR Newswire16 days ago

    Bausch Health Provides Company Update At The 37th Annual J.P. Morgan Healthcare Conference

    LAVAL, Quebec , Jan. 7, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") announced today it has published the presentation that Chairman and Chief Executive ...

  • The Zacks Analyst Blog Highlights: inTest, Progressive, BioTelemetry, Bausch Health and Steelcase
    Zacks16 days ago

    The Zacks Analyst Blog Highlights: inTest, Progressive, BioTelemetry, Bausch Health and Steelcase

    The Zacks Analyst Blog Highlights: inTest, Progressive, BioTelemetry, Bausch Health and Steelcase

  • The Wall Street Journal19 days ago

    [$$] Synergy Pharmaceuticals Wins Court Approval for Extended Sale Process

    Cos., formerly Valeant Pharmaceuticals International Inc., after agreeing to delay the process by two weeks. During a hearing Friday at the U.S. Bankruptcy Court in New York, Judge James Garrity Jr. said he was satisfied with the extension and was pleased to keep the process rolling forward. The judge had previously expressed concern about moving the sale along too quickly.

  • Bull or Bear: Your Investment Strategy for 2019
    Zacks19 days ago

    Bull or Bear: Your Investment Strategy for 2019

    Whether you're a bull or a bear, it may be a good idea to go defensive about now.

  • Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar
    Zacks20 days ago

    Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar

    Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.

  • Is Bausch Health Cos (BHC) Stock Outpacing Its Medical Peers This Year?
    Zacks20 days ago

    Is Bausch Health Cos (BHC) Stock Outpacing Its Medical Peers This Year?

    Is (BHC) Outperforming Other Medical Stocks This Year?

  • CNW Group20 days ago

    Bausch + Lomb Announces HEALTH CANADA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%) for the Treatment of Glaucoma

    Bausch + Lomb Announces HEALTH CANADA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%) for the Treatment of Glaucoma

  • ACCESSWIRE20 days ago

    Today's Research Reports on Trending Tickers: Bausch Health Companies and Cronos Group

    NEW YORK, NY / ACCESSWIRE / January 3, 2019 / U.S. equities closed up on Wednesday after a volatile trading day, as investors remained concerned over the Fed’s tighter monetary policy and possible economic ...

  • Why General Electric, Bausch Health, and Wynn Resorts Jumped Today
    Motley Fool21 days ago

    Why General Electric, Bausch Health, and Wynn Resorts Jumped Today

    Find out why these stocks climbed on the first trading day of the year.